drugset / Trial / NCT06792695

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695

Phase 2 Recruiting 80 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Timeline

Start
2025-03-12
Primary completion
2027-06-30
Completion
2028-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Volrustomig Monoclonal antibody Intravenous
Background Bevacizumab Monoclonal antibody Intravenous
Background Irinotecan Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous

Indications